Free Trial

RAPT Therapeutics (RAPT) Stock Price, News & Analysis

-0.16 (-4.60%)
(As of 06/14/2024 ET)
Today's Range
50-Day Range
52-Week Range
356,905 shs
Average Volume
594,481 shs
Market Capitalization
$115.87 million
P/E Ratio
Dividend Yield
Price Target

RAPT Therapeutics MarketRank™ Stock Analysis

Analyst Rating
2.31 Rating Score
643.0% Upside
$24.67 Price Target
Short Interest
7.62% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.63mentions of RAPT Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($2.93) to ($2.05) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.69 out of 5 stars

Medical Sector

45th out of 914 stocks

Pharmaceutical Preparations Industry

17th out of 429 stocks

RAPT stock logo

About RAPT Therapeutics Stock (NASDAQ:RAPT)

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

RAPT Stock Price History

RAPT Stock News Headlines

3 Biotech Stocks to Dump Before They Go to Zero
RAPT Apr 2024 10.000 put
RAPT Oct 2024 5.000 call
See More Headlines
Receive RAPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
13 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.53 million
Book Value
$4.27 per share


Free Float
Market Cap
$115.87 million

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Brian Russell Wong M.D. (Age 52)
    Ph.D., CEO, President & Director
    Comp: $861.24k
  • Mr. Rodney K. B. Young (Age 61)
    CFO, Principal Accounting Officer & Secretary
    Comp: $616.56k
  • Dr. William Ho M.D. (Age 58)
    Ph.D., Chief Medical Officer
    Comp: $620.32k
  • Steve Young Ph.D.
    Vice President of Technology
  • Dr. Dirk G. Brockstedt Ph.D. (Age 55)
    Chief Scientific Officer
    Comp: $490.25k
  • Mr. Michael Listgarten
    General Counsel
  • Ms. Gwen R. Carscadden (Age 63)
    Chief Human Resources Officer
  • Dr. Paul Kassner (Age 57)
    Senior Vice President of Quantitative & Computational Biology
  • Dr. David Wustrow (Age 65)
    Senior Vice President of Drug Discovery & Preclinical Development
  • Ms. Jennifer Nicholson
    Senior Vice President of Regulatory Affairs & Quality Assurance

RAPT Stock Analysis - Frequently Asked Questions

Should I buy or sell RAPT Therapeutics stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" RAPT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAPT, but not buy additional shares or sell existing shares.
View RAPT analyst ratings
or view top-rated stocks.

What is RAPT Therapeutics' stock price target for 2024?

13 Wall Street research analysts have issued 12-month price targets for RAPT Therapeutics' shares. Their RAPT share price targets range from $4.00 to $41.00. On average, they predict the company's stock price to reach $24.67 in the next year. This suggests a possible upside of 643.0% from the stock's current price.
View analysts price targets for RAPT
or view top-rated stocks among Wall Street analysts.

How have RAPT shares performed in 2024?

RAPT Therapeutics' stock was trading at $24.85 at the beginning of 2024. Since then, RAPT stock has decreased by 86.6% and is now trading at $3.32.
View the best growth stocks for 2024 here

When is RAPT Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024.
View our RAPT earnings forecast

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.78) by $0.01.

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics Chief Executive Officer Brian Wong on Brian Wong has an approval rating of 100% among the company's employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), Boeing (BA), Slack Technologies (WORK), (OSTK), Salesforce (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

RAPT Therapeutics (RAPT) raised $39 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (7.16%), Price T Rowe Associates Inc. MD (5.81%), Kingdon Capital Management L.L.C. (4.30%), Redmile Group LLC (1.90%), Affinity Asset Advisors LLC (0.00%) and Ikarian Capital LLC (0.00%). Insiders that own company stock include Dirk G Brockstedt, Dirk G Brockstedt, Gino Dellomo, Group Ii Lp Column, Phuong Y Phillips, Rodney Kb Young, Wendye Robbins and William Ho.
View institutional ownership trends

How do I buy shares of RAPT Therapeutics?

Shares of RAPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RAPT) was last updated on 6/16/2024 by Staff

From Our Partners